PepGen Halts DMD Therapy Research, Shares Down 9.5%

Summary

PepGen announced the cessation of its experimental therapy for Duchenne muscular dystrophy (DMD) as it failed to meet protein production targets in mid-stage studies. Following the announcement, the company’s stock price fell by 9.5% to $1.43. PepGen plans to halt all DMD-related research and focus on developing therapies for myotonic dystrophy, with early study data expected later this year and mid-stage results anticipated in early 2026.Reuters+ 2

Impact Analysis

First-Order Effects: The immediate impact is negative for PepGen due to the stock price decline following the announcement, reflecting investor disappointment over the failed DMD therapy. The strategic shift to focus on myotonic dystrophy introduces both risks and potential growth opportunities. There is uncertainty around the success of the new therapy, but it could position the company better if successful. Second-Order Effects: Competitors in the DMD therapy market may see reduced competitive pressure with PepGen’s exit, potentially benefiting from reallocated market resources and investor interest. Investment Opportunities: Investors might consider a cautious approach, possibly leveraging options strategies to hedge against further stock volatility while speculating on the potential success of the myotonic dystrophy program.Reuters+ 2